Los Angeles Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

Los Angeles Capital Management’s Portfolio UNCY Stock Details UNCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$446K	Buy	+95,019	New	+$701K	﹤0.01%	944

Other funds holding UNCY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Los Angeles Capital Management's UNCY Position: Q2 2026 in Review

Los Angeles Capital Management opened a new position in Unicycive Therapeutics (UNCY) in Q2 2026: 95,019 shares worth $446K. The stake represents ﹤0.01% of the portfolio and ranks #944 among its holdings.

80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

Los Angeles Capital Management held 95,019 shares of Unicycive Therapeutics worth $446K as of Q2 2026.
Unicycive Therapeutics was a new Los Angeles Capital Management position in Q2 2026.
Unicycive Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #944 holding.
80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.